NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMOWeiterlesen...
NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to AptarionWeiterlesen...
NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda® (Pembrolizumab) in panacreatic and colorectal CancerWeiterlesen...
NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated TherapiesWeiterlesen...
NOXXON Pharma N.V.: First Berlin startet Coverage mit Kaufempfehlung,
Kursziel EUR 40,00Weiterlesen...
THESE DATA WILL BE PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) CONFERENCE
Berlin, Germany, December 5, 2016, NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announces that it presented data at the ASH conference in San Diego, California studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) on Natural Killer (NK) cells in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment. These studies showed that NOX-A12 synergizes with NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Further studies of NOX-A12 with agents working through NK cell-based therapies are warranted.
CXCL12 Inhibition by NOX-A12 (Olaptesed Pegol) Synergizes With the ADCC Activity of CD20 Antibodies by Increasing NK Cell Infiltration in a 3D Lymphoma Model
Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater
Location & time:
58th ASH Annual Meeting, San Diego, CA, USA, Abstract #3021, Session 625 Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster II. Sunday, December 4, 2016 from 18:00 – 20:00
The poster may be downloaded from the company’s website: http://www.noxxon.com/downloads/poster/ash2016.pdf
NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12, may be a key partner for a wide range of IO (immuno-oncology) agents. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The Company believes that additional clinical trials are warranted to investigate combinations of NOX-A12 multiple classes of IO agents including those acting on or through T-cells and NK cells.